Skip to main content
About the Institute
  • English
  • Français
  • Español

Breadcrumb

  1. Home
  2. Microbiota 6 - March 2019
  3. Proton pump inhibitors modify gut microbiome
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographic
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
Dermatology

Breadcrumb

  1. Home
  2. Microbiota 6 - March 2019
  3. Proton pump inhibitors modify gut microbiome
Gastroenterology

Proton pump inhibitors modify gut microbiome

Drug interaction

Press review

By Pr. Markku Voutilainen
Turku University Faculty of Medicine; Turku University Hospital, Department of Gastroenterology, Turku, Finland

Gastroenterology
Gynecology
Pediatrics
Dermatology
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographic
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • Mail

Sections

About this article

Created 26 August 2021
Updated 05 January 2022

Proton pump inhibitors (PPIs), which are nowadays ones of the most widely used medicines even if about half of the prescriptions lack an evidence-based indication, have a central role in the treatment of peptic ulcer and gastro-oesophageal reflux disease. PPIs inhibit acid secretion from gastric parietal cells. PPI-induced hypochlorhydria may increase the risk of infections.

Mishiro et al. investigated the impact of 20 mg daily esomeprazole for 1 month on saliva, periodontal pocket fluid and fecal microbiota in 10 healthy volunteers.[1] Colonic microbiota contained the greatest number of species. Firmicutes, Bacteroidetes, Actinobacteria and Proteobacteria were the most abundant species in faeces, whereas Firmicutes, Proteobacteria, Bacteroidetes and Fusobacteria were the most common in saliva and periodontal pocket fluid. PPI caused a significant reduction in the diversity of salivary microbiota. Streptococci, which are predominantly found in the upper gastrointestinal tract, were increased in faeces and also in saliva and periodontal pocket after PPI treatment.[1]

Antibiotics and acid-suppressive medications cause dysbiosis. Stark et al. performed a retrospective study with 333,353 US children.[2] PPI prescriptions were associated with obesity, each additional antibiotic class increased the risk of obesity, and each additional 30-day prescription of acid-suppressive medication strengthened the association with obesity.

Mailhe et al. examined the gastrointestinal microbiota composition of 6 patients who underwent gastroscopy and colonoscopy.[3] Samples were obtained from stomach, duodenum, ileum, and colon. Culturomics was performed with mass spectometry MALDI-TOF and metagenomics targeting the V3-V4 region in the 16S rRNA. In all, 368 bacterial species were observed (37 new species): 110 from the stomach, 106 from the duodenum and 235 from the left colon. The upper gut contained less aero-intolerant species and less rich microbiota compared with the lower gut. Three patients used long-term PPI treatment; their gastric pH and bacterial diversity were higher compared with those not using PPI.

Investigators from Cleveland, have reviewed the impact of PPIs on gut microbiome [4]. The main consequence of PPI treatment is the increase in gastric pH. PPI treatment may lead to excess Streptococcus gastric colonisation, which may cause dyspeptic symptoms. Small bowel bacterial overgrowth risk is moderately increased during PPI treatment.[4] PPI and antibiotics increase Clostridium difficile infection (CDI) risk. PPI treatment may also increase spontaneous bacterial peritonitis risk in hepatic cirrhosis. A statistical association between PPI use and the incidence of Salmonella and Campylobacter infections has been reported.

Observational studies reporting associations between PPI use and side effects do not necessarily prove causal relationship. PPI users are often sicker than non-users, which could partially explain the increase of side effects. Anyhow, PPIs should be used only on evidence-based indications with lowest effective doses and should be stopped when the treatment response has been achieved.

Sources

1 Mishiro T, Oka T, Kuroki Y, et al. Oral microbiome alterations of healthy volunteers with proton pump inhibitor. J Gastroenterol Hepatol 2018 ; 33 : 1059-66.

2 Stark CM, Susi A, Emerick J, et al. Antibiotic and acid-suppression medications during early childhood are associated with obesity. Gut 2019 ; 68 : 62-9.

3 Mailhe M, Ribaconi D, Vitton V, et al. Repertoire of the gut microbiota from stomach to colon usin culturomics and next-generation sequencing. BMC Microbiol 2018 ; 18 : 157.

4 Singh A, Cresci GA, Kirby DF. Proton pump inhibitors: risks and rewards and emerging consequences to the gut microbiome. Nutr Clin Pract 2018 ; 33 : 614-24.

Tags
PPI Gastroenterology

en_view en_sources

    Focus
    Microbiota 6 - March 2019
    • Overview
      • Microbiota and celiac disease
    • Commented articles
      • Resilience of healthy adult gut microbiota following antibiotic exposure
      • Feeding practices from birth to 12 months: impact on the gut microbiota and the risk of being overweight
    • Congress review
      • Fecal transplantation - ready for prime time?
      • The gut microbiota: issues and challenges in the management of metabolic disorders
    • Press review
      • Proton pump inhibitors modify gut microbiome
      • Gut microbiota involved in the pathogenesis of non-alcoholic fatty liver disease
    Created 26 August 2021
    Updated 05 January 2022

    About this article

    To know more about this topic.

    Main topic

    Drug interaction

    Content type

    Press review
    The gut microbiota: issues and challenges in the management of metabolic disorders
    Gut microbiota involved in the pathogenesis of non-alcoholic fatty liver disease
    Focus

    Microbiota 6 - March 2019

    Overview

    Microbiota and celiac disease

    Commented articles

    Resilience of healthy adult gut microbiota following antibiotic exposure Feeding practices from birth to 12 months: impact on the gut microbiota and the risk of being overweight

    Congress review

    Fecal transplantation - ready for prime time? The gut microbiota: issues and challenges in the management of metabolic disorders

    Press review

    Proton pump inhibitors modify gut microbiome Gut microbiota involved in the pathogenesis of non-alcoholic fatty liver disease
    Gastroenterology
    22.11.2021

    Irritable bowel syndrome: is fecal microbiota transplantation effective in the long term?

    Read the article
    Cancer du pancréas : un diagnostic précoce non invasif grâce au microbiote fécal ?
    16.06.2022

    Pancreatic cancer: non-invasive early diagnosis thanks to the fecal microbiota?

    Read the article
    Photo: Régime méditerranéen « vert » : quels liens entre santé cardiométabolique et microbiote intestinal ?
    10.06.2022

    Green Mediterranean diet: what links between cardiometabolic health and gut microbiota?

    Read the article
    Immune checkpoint inhibitor (ICI) efficacy: the right dose of bacteria
    02.06.2022

    Immune checkpoint inhibitor (ICI) efficacy: the right dose of bacteria

    Read the article
    18.05.2022

    Gut microbiota and vitamin D: a promising team in the fight against osteoporosis?

    Read the article
    Photo: Neonatal sepsis: the microbiota pays a heavy price for antibiotic use
    09.05.2022

    Neonatal sepsis: the microbiota pays a heavy price for antibiotic use

    Read the article
    26.04.2022

    Severe obesity: the vicious circle of biotin metabolism

    Read the article
    22.04.2022

    SCFAs: new intestinal markers of Parkinson’s disease?

    Read the article
    What's worth reading about microbiota
    Follow us on Twitter
    Read our thematic folder
    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
    NL13_cover
    Check out latest newsletter
    IBS, Microbiota & Covid-19
    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology
    • English
    • Français
    • Español

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive once a month the “Microbiota Digest” to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    Photo: Postménopause : l'action bénéfique de l'estradiol sur le microbiote vaginal
    22.06.2022

    Postmenopause: the beneficial action of estradiol on the vaginal microbiota

    Read the article
    WMD_Foundation KOL USA 2018
    17.06.2022

    Dr. Yang (USA winner 2018): Gut microbiota & gut brain axis

    Read the article
    WMD_Foundation KOL USA 2017
    17.06.2022

    Dr. Singh (USA winner 2017): Microbiota & polyphenols

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive once a month the “Microbiota Digest” to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

    © 2022 Biocodex. All rights reserved.

    • Cookies Policy
    • Data protection policy
    • GTU
    • Sitemap
    • Cookies settings
    Biocodex logo